Condition: Metastatic Colon Cancer · Stage III Colon Cancer · Sponsor: Massachusetts General Hospital
This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance * FOLFIRI treatment * Nivolumab treatment * Encorafenib/Binimetinib/Cetuximab treatment * Trastuzumab + Pertuzumab
This description comes directly from the study's public registry record.
Aparna Parikh, MD · 617-724-4000 · Aparna.Parikh@MGH.HARVARD.EDU
Always discuss trial participation with your own doctor first.
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Weill Cornell Medical College | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03803553